

Fidson Healthcare Limited, a wholly indigenous pharmaceutical company, is a member of the Fidson Group, with corporate Head Office in
· Fidson has been very prominent in the Nigerian pharmaceutical industry since its entry. It attained a significant height in the industry when it emerged the first indigenous pharmaceutical company to manufacture anti-retroviral drug. The drug, known as Virex Anti-retroviral, was 100% formulated and manufactured in
· Fidson also displays outstanding performance records. Its compounded annual growth rates (CAGR) in turnover and after-tax profit have been 44.2% and 46.7% respectively. Similarly, the company has consistently paid dividend in each past financial year. At its last financial year ended June 30, 2007; the company declared and paid a dividend of N2.27 in addition to a bonus issue of 2 for 1 Ordinary share held by the existing shareholders. As at date, the company still has over N800 million as distributable reserves.
· As part of efforts to finance its growth and diversification plans, Fidson Healthcare Limited is planning to raise about N2.1 billion from the Nigerian Capital Market by privately placing 540 million Ordinary shares of 50k at a price of N3.95 each.



